Kaolin-based Hemostatic Gauze in Total Knee Arthroplasty

Status Recruiting

Clinical Trial Summary

This study is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of combination of intravenous TXA and QCG in a primary TKA procedure.

Clinical Trial Description

Total knee arthroplasty (TKA) is associated with considerable blood loss and increasing needs for allogenic blood transfusion. Previous studies demonstrated a transfusion rates ranging from 10% to 38% after standard TKAs. Tranexamic acid (TXA), an inhibitor of fibrinolysis, was reportedly effective reducing blood loss after standard TKA. Our previous experiences in minimally invasive (MIS) TKA showed that intraoperative intravenous infusion of TXA reduced 45% of postoperative blood loss and needs for transfusion from 20% to 4%. Our study demonstrated that an equal efficacy of intraarticular topical TXA in blood conservation compared with intravenous infusion of TXA. In addition to TXA, the Quikclot sponge (QCG; Z-Medica, Wallingford, CT, USA) is a newly developed hemostatic agent employing an inorganic mineral (kaolin). The QCG has predominantly been used in combat settings and trauma surgery. Recently, the application of QCG in interventional procedures, and non-orthopedic surgeries was reported. Literature describing the use of QCG as an alternative approach to achieve hemostasis in the field of orthopedics is limited. There is no study to investigate the blood-saving effect of QCG in a TKA procedure, especially in combined with TKA. Therefore we conduct the study to understand the efficacy of this sponge on blood conservation in TKA We believe that combination with the two different mechanism of blood-conservation agents can bring a synergistic effect in blood saving after TKA. Our purpose of this study therefore is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of QCG combined with TXA use. Material and Methods: The patients who are enrolled in this study will be randomly assigned into three groups. We plan to recruit 60 patients in each group (total case number is 120). The first group will be treated by application of QCG in joint space and TXA 1g intravenous injection before tourniquet deflation. The second group will be treated by application of normal gauze in joint space and TXA 1g intravenous injection before tourniquet deflation. The third group will be treated only TXA 1g intravenously injection alone before tourniquet deflation. We will observe whether there is difference in the blood-conservation effect by total blood loss calculation, hemoglobin loss and transfusion requirement between these three groups. Besides, any complications including VTE, deep infection, wound complications within postoperative 3 months will be recorded. Study years: two years ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05504577
Study type	Interventional
Source	Chang Gung Memorial Hospital
Contact	Shih-Hsiang Yen, MD
Phone	886-7-7317123
Email	yswings@cgmh.org.tw
Status	Recruiting
Phase	Phase 4
Start date	March 16, 2022
Completion date	July 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03506347` - Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement	Phase 2/Phase 3
Recruiting	`NCT01198340` - Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block	N/A
Completed	`NCT03364088` - Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia	N/A
Suspended	`NCT03601728` - A Personalized Prehabilitation Intervention In Elective Joint Replacement Surgery	N/A
Completed	`NCT03647709` - Opioid-free Accelerated Recovery Total Knee Arthroplasty
Recruiting	`NCT03339323` - The Effect of Exercise Training on Muscle Mass in Patients With Total Knee Arthroplasty	N/A
Completed	`NCT03668756` - Comparison of Computer-Assisted Navigation and Conventional Instrumentation for Bilateral Total Knee Arthroplasty
Completed	`NCT01548664` - The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement	Phase 2
Completed	`NCT01309035` - Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet	N/A
Completed	`NCT01364194` - Local Infiltration With Bupivacaine to Increase Quality of Post-operative Pain Control in Total Knee Replacement	Phase 4
Completed	`NCT01907178` - Postoperative Pain Management in Hospital and Following Discharge From Hospital.	N/A
Completed	`NCT03044028` - Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)	N/A
Completed	`NCT00967161` - Motion Analysis of EMP Knee Versus Posterior Stabilized Knee Arthroplasty for Osteoarthritis	N/A
Completed	`NCT01333189` - Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback	N/A
Completed	`NCT06124651` - Comparison of Cruciate Retaining and Posterior Stabilized Total Knee Arthroplasty	N/A
Recruiting	`NCT04814082` - Prospective Functional, Gait, and Outcome Comparison Study of Medial Pivot Versus Single Radius Design for Total Knee Arthroplasty	N/A
Completed	`NCT05266027` - Naldebain for Pain Management After Knee Arthroplasty	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.